Cencora Business Summary

Cencora, Inc. (COR) operates as a global pharmaceutical sourcing and distribution leader, generating the vast majority of its revenue through a high-volume, low-margin wholesale model. The company earns revenue by purchasing pharmaceuticals from manufacturers and distributing them to a diverse client base, including retail pharmacies, health systems, and physician practices. Its operations are structured into two primary segments: U.S. Healthcare Solutions, which handles domestic pharmaceutical distribution and specialty services, and International Healthcare Solutions, which encompasses global commercialization services and the Alliance Healthcare wholesale business. Cencora utilizes a fee-for-service model with manufacturers and captures margins on the price spread of generic and branded medications. In the highly consolidated pharmaceutical distribution market, Cencora competes directly with McKesson Corporation, Cardinal Health, and Henry Schein. As one of the "Big Three" distributors, Cencora maintains a dominant market position, leveraging its extensive cold-chain logistics and specialty pharmacy expertise to lead in high-growth sectors like oncology and cell-and-gene therapy. The company was established in 2001 through the merger of AmeriSource Health Corporation and Bergen Brunswig Corporation, tracing its institutional roots back over a century. Cencora is currently led by President and Chief Executive Officer Robert P. Mauch, who succeeded long-time leader Steven Collis in late 2024; Mauch previously served as Chief Operating Officer and has been a primary architect of the company’s integrated provider strategy. The executive leadership team includes James F. Cleary as Executive Vice President and Chief Financial Officer, and Mark Spykerman as Chief Information Officer, who directs the firm’s critical investments in data analytics and supply chain technology. The Board of Directors features seasoned leaders such as Kathleen W. Hyle and Mark Casper, providing oversight in global finance and operations. As a publicly traded S&P 500 entity, Cencora’s ownership is concentrated among major institutional investors, including The Vanguard Group and BlackRock, reflecting its status as a foundational component of the global healthcare infrastructure.